Premium
Are GLP ‐1 receptor agonists useful against traumatic brain injury?
Author(s) -
Combs Colin K.
Publication year - 2015
Publication title -
journal of neurochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.75
H-Index - 229
eISSN - 1471-4159
pISSN - 0022-3042
DOI - 10.1111/jnc.13224
Subject(s) - creb , liraglutide , neuroprotection , agonist , traumatic brain injury , glutamate receptor , receptor , sh sy5y , medicine , endocrinology , pharmacology , chemistry , neuroscience , biology , biochemistry , cell culture , neuroblastoma , psychiatry , transcription factor , type 2 diabetes , gene , diabetes mellitus , genetics
This Editorial highlights a study by Li et al . (2015) in the current issue of J. Neurochem . The image depicts the hypothesized neuroprotective pathway that is proposed by the authors. Using a combination of SH‐SY5Y and primary rat neuron cultures the GLP‐1R agonist, Liraglutide, was shown to increase SH‐SY5Y proliferation and CREB phosphorylation correlating with reduced toxicity, preservation of Bcl2 protein levels, and decreased caspase 3 activity following glutamate or H 2 O 2 stimulations. These in vitro observations correlated with a Liraglutide‐dependent improvement in memory performance in mice subjected to a mild TBI. Bcl2, B‐cell lymphoma 2; CREB, cAMP‐response element binding protein; GLP‐1R, glucagon‐like peptide 1 receptor; TBI, traumatic brain injury; PKA, protein kinase A.